The surprisingly simple treatment that could transform cancer care This low-tech intervention could fundamentally shift how we treat cancer patients.

Health Canada Approves KEYTRUDA® for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT)¹ Français ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in ...

Patient-reported outcomes from the OUTBACK trial highlight common, persistent sexual side effects that should be addressed following cervical cancer treatment.

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, with many patients quitting GLP-1 treatment within a year.

Akeso's Cadonilimab Gets NMPA Approval For First-line Cervical Cancer Treatment June 04, 2025 — 09:49 pm EDT Written by RTTNews.com for RTTNews -> ...

Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab Akeso's PD-1/CTLA-4 ...

Circulating tumor DNA (ctDNA) levels in patients with cervical cancer before and during treatment were prognostic of disease progression and survival in a post hoc analysis of the phase 3 CALLA ...

Exercise may significantly improve cancer outcomes, according to a groundbreaking study released this week in a major cancer journal.

Some benefits include mitigation of cardiac toxicity, peripheral neuropathy, cognitive impairment, and dyspnea. (HealthDay News) — Exercise mitigates adverse outcomes associated with cancer and ...

Current treatment options are limited for patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.